- Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
- Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
- Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
- Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Cameron Reynolds MBA
President & Group Chief Executive Officer
Cameron Reynolds is the President and Group Chief Executive Officer of Volition and was one of the founders of the company.
Cameron is the President and Group Chief Executive Officer of Volition and was one of the founders of the company in 2010. He is an experienced entrepreneurial executive, with expertise in a wide range of fields, including several biotechnology companies and has led Volition through the research and development of Volition’s proprietary Nucleosomics™ to the commercialization of its first test, the Nu.Q™ Vet Cancer Screening Test.
Cameron has extensive experience in the management, structuring, and financing of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, Chairman, and Non-Executive Director of public and private enterprises.
Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.
“I could not be more proud of the team we have put together who come to work every day to create a brighter future, one where hope and cancer can come together in the same sentence.”
Cameron Reynolds
President and Group Chief Executive Officer